🇺🇸 FDA
Pipeline program

Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets

GR-2021-12373041

Approved small_molecule active

Quick answer

Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets for patients with secondary progressive MS is a Approved program (small_molecule) at Verona Pharma Ireland Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Verona Pharma Ireland Limited
Indication
patients with secondary progressive MS
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials